May 7th 2024
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Biomarkers for bladder cancer: Current and future
April 18th 2017The role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.
Guidelines update: Bladder, kidney, prostate cancer
April 18th 2017This article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
Testis Ca care deviates from guidelines in 30% of patients
March 1st 2017Nearly one-third of men with testicular cancer undergo diagnostic or therapeutic interventions that are at odds with guidelines from the National Comprehensive Cancer Network (NCCN), according a study published in the Journal of Urology (2017; 197:684-9).
PD-1 inhibitor benefit possible even after discontinuation
February 21st 2017Persistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Antibiotics may negatively impact immunotherapy outcomes
February 21st 2017Administration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.
Uro Pipeline: FDA accepts biologics license application for bladder Ca agent
January 13th 2017Other pipeline developments discussed include an implantable device for OAB treatment, a subcutaneous hypogonadism treatment, efficacy results for an HPV drug, and the status of a device-based BPH treatment.
PCa immunotherapy: Response better when given before ADT
January 6th 2017Administering sipuleucel-T (Provenge) before rather than after androgen deprivation therapy in men with biochemically recurrent prostate cancer appears to result in a more robust immunologic response, according to a recent study.
How Sanofi’s discontinuation of BCG affects patients, clinicians
December 27th 2016Sanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.
High-grade bladder Ca: New data improve risk stratification
December 12th 2016“We need to identify those patients with high-grade T1 bladder cancer that are likely to recur or progress… and find additional options to prevent recurrence and progression in these patients,” said Joaquim Bellmunt, MD, PhD, in a presentation at the SUO annual meeting.